

Βιογραφικό Σημείωμα Ουρανίας Η. Τσιτσιλώνη

Διεύθυνση: Τομέας Φυσιολογίας Ζώων & Ανθρώπου, Τμήμα Βιολογίας ΕΚΠΑ, Πανεπιστημιούπολη 15784, Ιλίσια. Τηλ: 210-7274215, e-mail: rtsitsil@biol.uoa.gr

ΕΚΠΑΙΔΕΥΣΗ-ΣΠΟΥΔΕΣ

1986: Πτυχίο Βιολογίας, ΕΚΠΑ

1993: Διδάκτορας Βιολογικών Επιστημών, ΕΚΠΑ

1995: Πτυχίο Ιατρικής Σχολής, ΕΚΠΑ

ΕΠΑΓΓΕΛΜΑΤΙΚΗ ΣΤΑΔΙΟΔΡΟΜΙΑ

1993-1996: Μεταδιδακτορική ερευνήτρια, Τμήμα Βιολογίας, ΕΚΠΑ και Τμήμα Φυσιολογικής Χημείας, Πανεπιστήμιο Tuebingen, Γερμανία (Καθ. W. Voelter)

1996-1997: Άσκηση στην Ειδικότητα της Παθολογικής Ανατομικής-Κυτταρολογίας, ΑΟΝΑ «Αγ. Σάββας»

1998-1999: Εκπλήρωση υπηρεσίας υπαίθρου

1999-2002: Άσκηση στην Ειδικότητα της Ιατρικής Βιοπαθολογίας, ΓΟΝΚ «Αγ. Ανάργυροι» και ΑΟΝΑ «Αγ. Σάββας»

1996-2002: Επιστημονική συνεργάτης, Τμήμα Ανοσολογίας, ΑΟΝΑ «Αγ. Σάββας»

2002-2007: Λέκτορας Ανοσοβιολογίας, Τμήμα Βιολογίας, ΕΚΠΑ

2007-2014: Επίκουρη Καθηγήτρια Ανοσολογίας, Τμήμα Βιολογίας, ΕΚΠΑ

2014-2018: Αναπληρώτρια Καθηγήτρια Ανοσολογίας, Τμήμα Βιολογίας, ΕΚΠΑ

2018-σήμερα: Καθηγήτρια Ανοσολογίας, Τμήμα Βιολογίας, ΕΚΠΑ

2015-σήμερα: Αναπλ. Προέδρου Τμήματος Βιολογίας, ΕΚΠΑ

2016-σήμερα: Υπεύδυνη Μονάδας Κυτταρομετρίας Ροής, πιστοποιημένη κατά ISO 9001 : 2015

2019-σήμερα: Συνεργαζόμενη Καθηγήτρια (Ανοσολογία του Καρκίνου), Τμήμα Επιστημών Υγείας, Ευρωπαϊκό Πανεπιστήμιο Κύπρου

ΜΕΛΟΣ ΕΠΙΣΤΗΜΟΝΙΚΩΝ ΕΤΑΙΡΕΙΩΝ

Ιατρικός Σύλλογος Αθηνών, Ελληνική Εταιρεία Ανοσολογίας, Ελληνική Μικροβιολογική Εταιρεία, European Society of Clinical Microbiology and Infectious Diseases, Ελληνική Εταιρεία Βιολογικών Επιστημών, Πανελλήνια Ένωση Βιοεπιστημόνων (μέλος ΔΣ για τα έτη 2005-2006), Ελληνική Εταιρεία Ανοσο-Ογκολογίας (Ιδρυτικό μέλος και Γενική Γραμματέας 2015-σήμερα).

ΔΙΔΑΚΤΙΚΟ ΕΡΓΟ

ΠΠΣ Τμήματος Βιολογίας: Ανοσολογία (Συντονίστρια), Φυσιολογία Ζώων, Συγκριτική Φυσιολογία Ζώων, Ιστορία και Εξέλιξη της Βιολογίας, Νευροβιολογία

ΠΜΣ: Εφαρμογές της Βιολογίας στην Ιατρική (ΕΚΠΑ), Κλινική Βιοχημεία-Μοριακή Διαγνωστική (ΕΚΠΑ), Διδακτική της Βιολογίας (ΕΚΠΑ), Ενζυμική Βιοτεχνολογία (Γεωπονικό Πανεπιστήμιο Αθηνών), Ογκολογία Θώρακος (ΕΚΠΑ), Κλινική Χημεία (ΕΚΠΑ), Ιατρική Γενετική-Κλινική και Εργαστηριακή Κατεύθυνση (ΕΚΠΑ), Ογκολογία: από την Οικογένεση στη Θεραπεία (Πανεπιστήμιο Κρήτης), Ανάπτυξη νέων φαρμάκων: Έρευνα, κυκλοφορία και πρόσβαση (ΕΚΠΑ), Κλινικές Μελέτες: Σχεδιασμός και εκτέλεση (ΕΚΠΑ), Λοιμώδη Νοσήματα-Διεθνής Ιατρική (Δημοκρίτειο Πανεπιστήμιο Θράκης).

ΕΡΕΥΝΗΤΙΚΕΣ ΕΠΙΧΟΡΗΓΗΣΕΙΣ

Γενική Γραμματεία Έρευνας και Τεχνολογίας (ΓΓΕΤ), DLR-DAAD (Jülich και Βόννη), Ευρωπαϊκή Ένωση, NATO-SfP, Υπουργείο Υγείας (ΚΕΣΥ), Υπουργείο Παιδείας, Έρευνας και Θρησκευμάτων, ΕΚΠΑ-ΕΛΚΕ, Ίδρυμα Κρατικών Υποτροφιών (ΙΚΥ), Εμπειρικό Ίδρυμα, Ίδρυμα Λάτση, ΕΛΙΔΕΚ, ΕΟΠΕ.

ΕΠΙΛΕΓΜΕΝΕΣ ΔΗΜΟΣΙΕΥΣΕΙΣ (τελευταία 10 έτη)

1. Gavalas NG, Tsiatas M, **Tsitsilonis O**, Politi E, Ioannou K, Ziogas AC, Rodolakis A, Vlahos G, Thomakos N, Haidopoulos D, Terpos E, Antsaklis A, Dimopoulos MA, Bamias A. VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. *Br. J. Cancer* 107: 1869-75, 2012.
2. Voutsas IF, Pistamaltzian N, Tsiatas ML, Skopeliti M, Katsila T, Mavrothalassiti E, Spyrou S, Dimopoulos MA, **Tsitsilonis OE**, Bamias A. Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin alpha or its immunoinactive decapeptide lyse autologous tumor cells in vitro and retard tumor growth in SCID mice. *Eur. J. Cancer* 49:1706-14, 2012.

3. Baxevanis CN, Voutsas IF, **Tsitsilonis OE**. Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies. *Immunotherapy* 5:497-511, 2013.
4. Samara P, Kalbacher H, Ioannou K, Radu DL, Livaniou E, Promponas VJ, Voelter W, **Tsitsilonis O**. Development of an ELISA for the quantification of the C-terminal decapeptide prothymosin α (100-109) in sera of mice infected with bacteria. *J. Immunol. Meth.* 395: 54-62, 2013.
5. Ioannou K, Derhovanessian E, Tsakiri E, Samara P, Kalbacher H, Voelter W, Trougakos IP, Pawelec G, **Tsitsilonis OE**. Prothymosin α and a prothymosin α -derived peptide enhance TH1-type immune responses against defined HER-2/neu epitopes. *BMC Immunol.* 14: 43-49, 2013.
6. Ioannou K, Cheng KF, Crichlow GV, Birmopilis AI, Lolis EJ, **Tsitsilonis OE**, Al-Abed Y. ISO-66, a novel inhibitor of macrophage migration inhibitory factor, shows efficacy in melanoma and colon cancer models. *Int. J. Oncol.* 45: 1457-68, 2014.
7. Kostopoulos IV, Paterakis G, Papadimitriou K, Pavlidis D, **Tsitsilonis OE**, Papadimitriou SI. Immunophenotypic analysis reveals heterogeneity and common biologic aspects in monoclonal B-cell lymphosytosis. *Genes Chromosomes Cancer* 54: 210-21, 2015.
8. Papaioannou NE, Voutsas IF, Samara P, **Tsitsilonis OE**. A flow cytometric approach for studying alterations in the cytoplasmic concentration of calcium ions in immune cells following stimulation with thymic peptides. *Cell. Immunol.* 302:32-40, 2016.
9. Samara P, Ioannou K, **Tsitsilonis OE**. Prothymosin alpha and immune responses: are we close to potential clinical applications? *Vitam. Horm.* 102:179-207, 2016.
10. Papaioannou NE, Beniata OV, Vitsos P, **Tsitsilonis O**, Samara P. Harnessing the immune system to improve cancer therapy. *Ann. Transl. Med.* 4:261, 2016.
11. Goldeck D, Theeten H, Hassouneh F, Oettinger L, Wistuba-Hamprecht K, Cools N, **Tsitsilonis OE**, Pawelec G. Frequencies of peripheral immune cells in older adults following seasonal influenza vaccination with an adjuvanted vaccine. *Vaccine* 35:4330-4338, 2017.
12. Samara P, Miriagou V, Zachariadis M, Mavrofydi O, Promponas VJ, Dedos SG, Papazafiri P, Kalbacher H, Voelter W, **Tsitsilonis O**. A fragment of the alarmin prothymosin α as a novel biomarker in murine models of bacterial-induced sepsis. *Oncotarget* doi: 10.18632/oncotarget.18149, 2017.
13. Kostopoulos IV, Paterakis G, Pavlidis D, Kastritis E, Terpos E, **Tsitsilonis OE**, Papadimitriou SI. Clonal evolution is a prognostic factor for the clinical progression of monoclonal B-cell lymphocytosis. *Blood Cancer J.* 7:e597, 2017.
14. Cheimonidi C, Samara P, Polychronopoulos P, Tsakiri EN, Nikou T, Myriantopoulos V, Sakellaropoulos T, Zoumpourlis V, Mikros E, Papassideri I, Argyropoulou A, Halabalaki M, Alexopoulos LG, Skaltsounis AL, **Tsitsilonis OE**, Aligiannis NN, Trougakos IP. Selective cytotoxicity of the herbal substance acteoside against tumor cells and its mechanistic insights. *Redox Biol.* 16:169, 2018.
15. Kastritis E, Kostopoulos IV, Terpos E, Paiva B, Fotiou D, Gavriatopoulou M, Kanellias N, Ziogas DC, Roussou M, Migkou M, Eleutherakis-Papaiakovou E, Trougakos IP, **Tsitsilonis O**, Dimopoulos MA. Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. *Blood Cancer J.* 8:46, 2018.
16. Karachaliou CE, Kalbacher H, Voelter W, **Tsitsilonis OE**, Livaniou E. In vitro immunodetection of prothymosin alpha in normal and pathological conditions. *Curr. Med. Chem.* doi: 10.2174/0929867326666190807145212, 2019.
17. Kastritis E, Dialoupi I, Gavriatopoulou M, Roussou M, Kanellias N, Fotiou D, Ntanasis-Stathopoulos I, Papadopoulou E, Ziogas DC, Stamatelopoulos K, Manios E, Ntalianis A, Eleutherakis-Papaiakovou E, Papanikolaou A, Migkou M, Papanota AM, Gakiopoulou H, Psimenou E, Tselegkidi MI, **Tsitsilonis O**, Kostopoulos I, Terpos E, Dimopoulos MA. Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide and dexamethasone. *Blood Adv.* 3:3002, 2019.
18. Birmopilis AI, Karachaliou CE, Samara P, Ioannou K, Selemenakis P, Kostopoulos IV, Kavrochorianou N, Kalbacher H, Livaniou E, Haralambous S, Kotsinas A, Farzaneh F, Trougakos IP, Voelter W, Dimopoulos MA, Bamias A, **Tsitsilonis O**. Antitumor reactive T cell responses are enhanced in vivo by DAMP prothymosin alpha and its C-terminal decapeptide. *Cancers (Basel)* doi: 10.3390/cancers1111764, 2019.
19. Amanatidou AI, Nastou KC, **Tsitsilonis OE**, Iconomidou VA. Visualization and analysis of the interaction network of proteins associated with blood-cell targeting autoimmune diseases. *Biochim Biophys Acta Mol. Basis Dis.* 1866:165714, 2020.
20. Iliou A, Panagiotakis A, Giannopoulou AF, Benaki D, Kosmopoulou M, Velentzas AD, **Tsitsilonis OE**, Papassideri IS, Voutsinas GE, Konstantakou EG, Gikas E, Mikros E, Stravopodis DJ. Malignancy grade-dependent mapping of metabolic landscapes in human urothelial bladder

- cancer: identification of novel, diagnostic and druggable biomarkers. *Int. J. Mol. Sci.* 21:18792, 2020.
21. Kostopoulos IV, Ntanasis-Stathopoulos I, Gavriatopoulou M, **Tsitsilonis OE**, Terpos E. Minimal residual disease in Multiple Myeloma: current landscape and future applications with immunotherapeutic approaches. *Front. Oncol.* 10:860, 2020.
 22. **Tsitsilonis OE**, Paraskevis D, Lianidou E, Pierros V, Akalestos A, Kastritis E, Moutsatsou P, Scorilas A, Sphicopoulos T, Terpos E, Thomaidis N, Tsakris A, Voulgaris N, Daskalaki CC, Evangelakou Z, Fouki C, Gianniou DD, Gumeni S, Kostaki EG, Kostopoulos IV, Manola MS, Orologas-Stavrou N, Panteli C, Papanagnou ED, Rousakis P, Sklirou AD, Smilkou S, Stergiopoulou D, Trougakos IP, Tsiodras S, Sfikakis PP, Dimopoulos MA. Seroprevalence of antibodies against SARS-CoV-2 among the personnel and students of the National and Kapodistrian University of Athens, Greece: a preliminary report. *Life (Basel)* 10:214, 2020.
 23. Papadimitriou K, Tsakirakis N, Malandrakis P, Vitsos P, Metousis A, Orologas-Stavrou N, Ntanasis-Stathopoulos I, Kanellias N, Eleutherakis-Papaiakovou E, Pothos P, Fotiou D, Gavriatopoulou M, Kastritis E, Dimopoulos MA, Terpos E, **Tsitsilonis OE**, Kostopoulos IV. Deep phenotyping reveals distinct immune signatures correlating with prognostication, treatment responses, and MRD status in Multiple Myeloma. *Cancers (Basel)* 12:3245, 2020.
 24. Orologas-Stavrou N, Politou M, Rousakis P, Kostopoulos IV, Ntanasis-Stathopoulos I, Jahaj E, Tsiligkeridou E, Gavriatopoulou M, Kastritis E, Kotanidou A, Dimopoulos MA, **Tsitsilonis OE**, Terpos E. Peripheral blood immune profiling of convalescent plasma donors reveals alterations in specific immune subpopulations even at 2 months post SARS-CoV-2 infection. *Viruses* 13:26, 2020.
 25. Trougakos IP, Stamatelopoulos K, Terpos E, **Tsitsilonis OE**, Aivalioti E, Paraskevis D, Kastritis E, Pavlakis GN, Dimopoulos MA. Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. *J. Biomed. Sci.* 28:9, 2021.
 26. **Tsitsilonis OE**, Paraskevis D, Lianidou E, Terpos E, Akalestos A, Pierros V, Kostaki EG, Kastritis E, Moutsatsou P, Scorilas A, Sphicopoulos T, Thomaidis N, Trougakos IP, Tsakris A, Vourgarris N, Daskalaki CC, Evangelakou Z, Fouki C, Gianniou DD, Gumeni S, Kostopoulos IV, Manola MS, Orologas-Stavrou N, Panteli C, Papanagnou ED, Rousakis P, Sklirou AD, Smilkou S, Stergiopoulou D, Tsiodras S, Dimopoulos MA, Sfikakis PP. SARS-CoV-2 infection is asymptomatic in nearly half of adults with robust anti-spike protein receptor-binding domain antibody response. *Vaccines (Basel)* 9:207, 2021.
 27. Tzounakas VL, Anastasiadi AT, Stefanoni D, Cendali F, Bertolone L, Gamboni F, Dzieciatkowska M, Rousakis P, Vergaki A, Soulikis V, **Tsitsilonis OE**, Stamoulis K, Papassideri IS, Kriebardis ANG, D'Alessandro A, Antonelou MH. β -thalassemia minor is a beneficial determinant of red blood cell storage lesion. *Haematologica* doi: 10.3324/haematol.2020.273946, 2021.
 28. Cheimonidi C, Grivas IN, Sesti F, Kavrochorianou N, Gianniou DD, Taoufik E, Badounas F, Papassideri I, Rizzi F, **Tsitsilonis OE**, Haralambous S, Trougakos IP. Clusterin overexpression in mice exacerbates diabetic phenotypes but suppresses tumor progression in a mouse melanoma model. *Aging (Albany NY)* 13:6485, 2021.
 29. Tsoumani M, Georgoulis A, Nikolaou PE, Kostopoulos IV, Dermintzoglou T, Papatheodorou I, Zoga A, Efentakis P, Konstantinou M, Gikas E, Kostomitsopoulos N, Papapetropoulos A, Lazou A, Skaltsounis AL, Hausenloy DJ, **Tsitsilonis O**, Tseti I, Di Lisa F, Iliodromitis EK, Andreadou I. Acute administration of the olive constituent, oleuropein, combined with ischemic postconditioning increases myocardial protection by modulating oxidative defense. *Free Radic. Biol. Med.* 166:18, 2021.
 30. Kostopoulos IV, Orologas-Stavrou N, Rousakis P, Panteli C, Ntanasis-Stathopoulos I, Charitaki I, Korompoki E, Gavriatopoulou M, Kastritis E, Trougakos IP, Dimopoulos MA, **Tsitsilonis OE**, Terpos E. Recovery of innate immune cells and persisting alterations in adaptive immunity in the peripheral blood of convalescent plasma donors at eight months post SARS-CoV-2 infection. *Microorganisms* 9:546, 2021.
 31. Kostopoulos IV, Eleutherakis-Papaiakovou E, Rousakis P, Ntanasis-Stathopoulos I, Panteli C, Orologas-Stavrou N, Kanellias N, Malandrakis P, Liacos CI, Papaioannou NE, Papanota AM, Migkou M, Fotiou D, Gavriatopoulou M, Angelis NV, Kastritis E, Dimopoulos MA, **Tsitsilonis OE**, Terpos E. Aberrant plasma cell contamination of peripheral blood stem cell autografts, assessed by next-generation flow cytometry, is a negative predictor for deep response post autologous transplantation in Multiple Myeloma; A Prospective Study in 199 Patients. *Cancers (Basel)* 13:4047, 2021.
 32. Giannopoulou AF, Velentzas AD, Anagnostopoulos AK, Agalou A, Papandreou NC, Katarachia SA, Koumoundourou DG, Konstantakou EG, Pantazopoulou VI, Delis A, Michailidi MT, Valakos D, Chatzopoulos D, Syntichaki P, Iconomidou VA, **Tsitsilonis OE**, Papassideri IS, Voutsinas GE, Hatzopoulos P, Thanos D, Beis D, Anastasiadou E, Tsangaris GT, Stravopodis DJ. From

- Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis. *Cancers (Basel)* 13:2024, 2021.
33. Valiakou V, Eliadis P, Karamichali E, **Tsitsilonis O**, Koskinas J, Georgopoulou U, Foka P. Differential Expression of the Host Lipid Regulators ANGPTL-3 and ANGPTL-4 in HCV Infection and Treatment. *Int. J. Mol. Sci.* 22:7961, 2021.
 34. Karamitros T, Pogka V, Papadopoulou G, **Tsitsilonis O**, Evangelidou M, Sympardi S, Mentis A. Dual RNA-Seq Enables Full-Genome Assembly of Measles Virus and Characterization of Host-Pathogen Interactions. *Microorganisms* 9:1538, 2021.
 35. Kastritis E, Rousakis P, Kostopoulos IV, Gavriatopoulou M, Theodorakakou F, Fotiou D, Dialoupi I, Migkou M, Roussou M, Kanellias N, Tselegkidi MI, Eleutherakis-Papaiakovou E, Papanikolaou A, Gakiopoulou C, Psimenou E, Spyropoulou-Vlachou M, Gatou A, Terpos E, **Tsitsilonis O**, Dimopoulos MA. Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease. *Amyloid* 2021 (in press).